elacestrant (Orserdu) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Elacestrant, sold under the brand name Orserdu, is an anticancer medication which is used in the treatment of breast cancer. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1
  • InChIKey: SIFNOOUKXBRGGB-AREMUKBSSA-N
  • Mol. Mass: 458.65
  • ALogP: 5.85
  • ChEMBL Molecules:
    rad1901  
    elacestrant  
More Chemistry

Pharmacology

Alternative names

rad1901 | rad-1901

Organizations (15)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Brain Diseases (Phase 1/Phase 2)

Brain Neoplasms (Phase 1/Phase 2)

Breast Diseases (Phase 1/Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Central Nervous System Diseases (Phase 1/Phase 2)

Central Nervous System Neoplasms (Phase 1/Phase 2)

Hot Flashes (Phase 2)

Liver Diseases (Phase 1)

Neoplasms (Phase 2)

Neoplasms by Site (Phase 1/Phase 2)

Vasomotor System (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue